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Abstract 
Both radiographic (Rad) imaging, such as multi-parametric magnetic resonance imaging, and digital 
pathology (Path) images captured from tissue samples are currently acquired as standard clinical practice 
for glioblastoma tumors. Both these data streams have been separately used for diagnosis and treatment 
planning, despite the fact that they provide complementary information. In this research work, we aimed 
to assess the potential of both Rad and Path images in combination and comparison. An extensive set of 
engineered features was extracted from delineated tumor regions in Rad images, comprising T1, T1-Gd, 
T2, T2-FLAIR, and 100 random patches extracted from Path images. Specifically, the features comprised 
descriptors of intensity, histogram, and texture, mainly quantified via gray-level-co-occurrence matrix and 
gray-level-run-length matrices. Features extracted from images of 107 glioblastoma patients, downloaded 
from The Cancer Imaging Archive, were run through support vector machine for classification using leave-
one-out cross-validation mechanism, and through support vector regression for prediction of continuous 
survival outcome. The Pearson correlation coefficient was estimated to be 0.75, 0.74, and 0.78 for Rad, 
Path and RadPath data. The area-under the receiver operating characteristic curve was estimated to be 
0.74, 0.76 and 0.80 for Rad, Path and RadPath data, when patients were discretized into long- and short-
survival groups based on average survival cutoff. Our results support the notion that synergistically using 
Rad and Path images may lead to better prognosis at the initial presentation of the disease, thereby 
facilitating the targeted enrollment of patients into clinical trials. 
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1. Introduction 
Glioblastoma is a frequent and aggressive malignant adult brain tumor, with poor prognosis and 
heterogeneous molecular1 and imaging2 landscape. The median overall-survival of glioblastoma patients 
is ~14-16 months after standard-of-care treatment, or possibly a bit longer with some emerging advanced 
treatments3, and ~4 months otherwise4. Although the currently applicable treatment options, which 
include surgical resection, radiotherapy, and chemotherapy, have expanded during the last couple of 
decades, the prognosis still remains poor for this devastating disease. A major obstacle in treating 
glioblastoma patients is the heterogeneity of their molecular and imaging profiles 5,6, which renders the 
clinical practice of the same treatment for all inadequate.  
Both radiographic (Rad) imaging such as multi-parametric magnetic resonance imaging (MRI), and digital 
pathology (Path) images captured from tissue samples are routinely acquired as standard clinical practice 
for glioblastoma patients. Both these data streams provide comprehensive information, but are 
separately used for diagnosis and treatment planning, despite the fact that they provide complementary 
information. However, the combination of these imaging sequences under the umbrella of emerging field 
of radiopathomics may lead to better diagnosis compared to either of the individual imaging sequences 
alone. 
Previously, it has been shown that both Rad and Path images based signatures can independently predict 
outcome of interest. For example, MRI based signatures of epidermal growth factor receptor variant III 
(EGFRvIII) mutation 7, isocitrate dehydrogenase-1 (IDH1) mutational status8, and O6-methylguanine–DNA 
methyltransferase (MGMT) methylation status 9, and Path  based signatures of IDH and 1p/19q mutation 
10,11 are indicative of the fact that both these imaging sequences manifest the biology of the tumor and 
hence lead to prediction of outcome of interest. Likewise, it has also been shown in the recent literature 
that MRI12 and Path10,11,13 can both lead to assessment of survival of brain tumors. Lately, Shukla et al. 
presented that the features extracted from MRI offer additional predictive value to the survival 
assessment acquired by using clinical and genomic biomarkers only in the TCGA glioblastoma patients 14. 
Results by another group on the same dataset also confirmed better prognostication when Path images 
and genomic biomarkers (IDH, 1p/19q) were used together15. These data and some other studies on 
prostate cancer 16,17 support the hypothesis that combined evaluation of Rad and Path images will even 
further improve prognostication, and will enhance our understanding of the disease. Therefore, objective 
of this study is to apply supervised learning algorithm on multiple data streams to exploit the 
complementary information provided by these imaging sequences for improved prognostication. We 
integrated and analyzed the entirety of Rad and Path imaging data, leveraging advanced pattern analysis 
methods.  
These advanced methods enable the extraction of quantitative imaging features and subsequently unique 
imaging phenotypes, which are hard to appreciate either via visual analysis of images or by analysis of 
individual features. In this research study, we aim to use advanced image analysis to demonstrate the 
ability of integrated radiomics and pathomics data for assessment of survival of glioblastoma patients.  
2. Materials and Methods 
2.1 Study Setting and Data Source 
The data of 107 glioblastoma patients involved in this study was acquired from The Cancer Image Archive 
(TCIA) and The Cancer Genomic Atlas (TCGA). The criteria to include patients in the study were availability 
of: (i) pre-operative MRI data, including T1-weighted (T1), T1 post contrast gadolinium (T1-Gd), T2-
weighted (T2), and T2 fluid attenuated inversion recovery (T2-FLAIR) images, (ii) corresponding digital 
pathology images, and (iii) overall-survival outcome. The overall-survival of these patients was 
downloaded from clinical records provided by TCIA. The patients were acquired under different scanners 
and image acquisition methods in different institutions, which allowed testing of the robustness of the 
method across different institutions.  
2.2 Image Preprocessing 
Considering the totally different nature of imaging sequences involved in the study, two separate image 
processing pipelines were used to process Rad and Path images (Fig.1). 
Rad (MRI) images: DICOM import routines available in SPM8 were used to convert the MRI images to 
stereoscopic T1, T2, T2-FLAIR and T1-Gd volumetric images. The MRI image sequences were smoothed in 
order to reduce intensity-based noise in image regions having uniform intensity profile. An adaptive non-
local means algorithm18,19, which is an extended version of traditional non-local means algorithm, was 
used for de-noising. The optimal parameters for de-noising were obtained using a previously proposed 
method20. For correction of bias in MRI scans caused due to magnetic field inhomogeneities, N4 bias 
correction algorithm was used to correct for intensity non-uniformities caused by the magnetic field of 
the scanner during image acquisition21. Registration and skull-stripping were, respectively, performed by 
the Linear Image Registration Tool (FLIRT) and Brain Extraction Tool (BET)22. The histogram matching was 
performed on the images by selecting all the images of one patient as a reference template.  
Path images: All the Path images were manually checked for artifacts, and the images free of all types of 
artifacts were chosen. The images were then converted to gray-scale using matlab routines before further 
image processing.  
 
 
Figure 1: Image processing workflow. 1. Pre-processed MRI images and tissue specimen. 2. Delineation of tumor sub regions in 
MRI scan, and extraction of random patches from Path image. 3. Radiographic and pathologic characteristics of long and short 
survivors. 5. Extracted radiomic features from MRI, and radiomic and nuclei features from Path images. 5. Machine learning 
regression for prediction of overall-survival, and machine learning classification to model survival prediction as a binary 
classification problem between long- and short-survivors.  
2.3 Region Annotation 
Specific regions were either delineated or extracted from Rad and Path images to derive features for the 
classification problem.  
Path images: A set of 100 region-of-interest each comprising 1024x1024 pixels which had viable tissue 
with vivid histopathologic characteristics and that were free of artifacts were extracted from Path images. 
The patches were selected in a way to make sure that they cover atleast 50% of the tissue area (Fig. 2a).  
Rad images: Different tumor sub-regions comprising enhancing tumor (ETumor), nonenhancing tumor 
(non-ETumor) core, peritumoral edema region or invasion (Edema), and ventricles (Vent) were manually 
delineated (Fig. 2b). 
 
(a) 
 
(b) 
Figure 2: Region annotation in Path and Rad images: (a) 100 patches of size 1024x1024 pixels were extracted from the whole slide 
Path image, (b) tumor region delineated into different tumor sub-regions, including ETumor (blue), Non-ETumor (red), and Edema 
(green). 
2.4 Feature Extraction 
Following the definition of these ROIs, all Rad and Path images were analyzed to extract relevant 
comprehensive quantitative imaging phenomics features from the corresponding ROIs, in order to create 
our predictive model. 
Path images: A reconstruction algorithm based on fast hybrid grayscale was employed to normalize the 
background region and to get rid of the artifacts introduced by the scanning and tissue cutting process23. 
A simple threshold-based mechanism was employed to extract the foreground nuclei from the normalized 
background region, followed by watershed segmentation algorithm for proper delineation of overlapped 
nuclei24. Four complementary types of features were extracted from segmented nuclei. The features 
include size, morphometry, nuclear intensity and gradient statistics, and texture descriptors summarizing 
the content and distribution of chromatin within nuclei. In addition, a comprehensive set of traditional 
radiomic texture features such as local binary patterns (LBP)25, gray-level size-zone matrix (GLSZM)26,27, 
neighborhood gray-tone difference matrix (NGTDM)28, gray-level co-occurrence matrix (GLCM)29, and 
gray-level run-length matrix (GLRLM)26 were also extracted.  
Rad (MRI) images: Several features were extracted from each delineated tumor sub-region i.e. Edema, 
Non-ETumor, and ETumor. The features included: volumetric measures of tumor sub-regions; anatomical 
location of the tumor; distance, in millimeter, of ETumor and Edema from ventricles; first order statistical 
moments of intensities of each Rad sequence in Edema, Non-ETumor, and ETumor; frequency of 
intensities of each Rad sequence in five equal-sized distribution bins in ETumor, non-ETumor, and Edema; 
the summarized signal of the intensity distribution histogram of each Rad sequence using Principal 
Component Analysis (PCA); age; and gender. A comprehensive set of traditional radiomic texture features, 
as extracted from Path images, including LBP25, NGTDM28, GLSZM26,27, GLCM29, GLRLM26 was also 
extracted. To obtain these texture features in 3 dimensions, all mpMRI volumes were first quantized to 
16 gray levels within the ROI. A neighborhood of 3x3x3 was considered for GLCM. These features were 
first computed for each of the 13 main directions independently, and then averaged to find their final 
value. All features were rescaled via z-score normalization before further analysis. 
2.5 Machine learning and correlation analysis 
Support Vector Machines (SVM), a pattern classification approach, was used to construct a classifier, to 
predict long- and short-survivors. Linear kernel of SVM was employed for this multivariate analysis, and 
the parameters of the classifier were optimized using cross-validated grid search (5-fold) on the training 
data. The classifier was trained separately using leave-one-out cross-validation (LOOCV) schema within 
training and validation sets and each time one of the three types of features was used, i.e., Rad, Path and 
RadPath. To confirm the robustness, accuracy, and generalizability of the method in a larger cohort, while 
avoiding optimistically biased estimates of performance, we have also evaluated the classifiers in all 107 
patients using a LOOCV schema, and in a split-train-test mechanism by training the classifier on the 
training cohort (n=54) and testing on the validation cohort (n=53). 
In addition to identifying an imaging signature to distinguish between long- and short-survivors, we also 
tried to find the correlations between the features and the overall-survival. This approach should identify 
complementary information of the extracted features by their correlations with long- and short-survivors. 
To achieve this, we used all 107 patients and trained separate support vector regression (SVR) models in 
a LOOCV configuration for the prediction of survival with continuous values.  
3. Results 
3.1 Performance of the proposed radiopathomics regression model 
Pearson correlation coefficient (ρ) and area under the curve (AUC) were employed for evaluation. A boost 
in performance [ρ=0.79, AUC=0.768] was observed using RadPath images compared to either Rad [ρ=0.75, 
AUC=0.76] or Path [ρ=0.75, AUC=0.73] features on combined dataset in a LOOCV setting (top row Fig.3). 
The regression models based on Rad and Path images were able to yield [ρ=0.73, AUC=0.76] and [ρ=0.74, 
AUC=0.78], respectively, in split-train-test configuration. However, the performance improved 
considerably when the features extracted from both the image types were used together in the regression 
model. A higher correlation of 0.79 and AUC 0f 0.80 indicates that a significant improvement in survival 
prediction is achieved when both the image types are used together (bottom row Fig.3). Also, Similarly, 
the regression models developed using RadPath features on training and validation cohorts were able to 
yield [ρ=0.81, AUC=0.79] and [ρ=0.80, AUC=0.79], respectively. The corresponding performance was 
[ρ=0.74, AUC=0.78] and [ρ=0.75, AUC=0.73] using Rad, and was [ρ=0.74, AUC=0.73] and [ρ=0.73, 
AUC=0.70] using Path images.  
 
Figure 3: Correlation analysis of the scores of different experiments: Top-row and bottom row, respectively, show classification 
results for LOOCV on complete dataset and the split-train-test experiment. Left to right show Rad, Path, and RadPath features, 
respectively. 
3.2 Performance of the radiopathomics classification model 
The accuracy of the model in predicting long and short survivors was 81.82% in the training cohort, 80.77% 
in the validation cohort, and 82.24% in the combined cohort using Rad features only in a LOOCV setting 
(results given in Table 1). The cross-validated classification performance of the model was 85.45% in the 
training cohort, 82.69% in the validation cohort, and 85.05% in the combined cohort using Path features 
only. The performance further improved with RadPath features yielding an accuracy of 90.91% in the 
training cohort, 86.54% in the validation cohort, and 90.65% in the combined cohort. Overall, 2-way 
classification into short and long survivors was 75.00%, 78.85%, and 84.62% using Rad, Path, and RadPath 
features, respectively, in the split-train-test setting. The corresponding ROC curves are in Fig.4.  
 Table 1: Quantitative evaluation of the proposed model using Rad, Path and RadPath feature sets in various classification settings: 
LOOCV in training, validation and combined datasets, and a model applied on replication data after being trained on the training 
dataset. 
 Accuracy Sensitivity Specificity AUC, S.E. [95% CI] 
Rad 
LOO (Training) 81.82 82.14 81.48 0.84, 0.06 [0.73-0.95] 
LOO (Validation) 80.77 80.77 80.77 0.80, 0.06 [0.68-0.92] 
LOO (Combined) 82.24 81.48 83.02 0.83, 0.04 [0.75-0.91] 
Split-Train-Test 75.00 73.08 76.92 0.72, 0.07 [0.58-0.86] 
Path     
LOO (Training) 85.45 82.14 88.89 0.84, 0.06 [0.73-0.95] 
LOO (Validation) 82.69 80.77 84.62 0.83, 0.06 [0.72-0.95] 
LOO (Combined) 85.05 85.19 84.91 0.83, 0.04 [0.75-0.91] 
Split-Train-Test 78.85 76.92 80.77 0.74, 0.07 [0.60-0.88] 
RadPath 
LOO (Training) 90.91 89.29 92.59 0.89, 0.05 [0.80-0.98] 
LOO (Validation) 86.54 84.62 88.46 0.89, 0.05 [0.80-0.98] 
LOO (Combined) 90.65 90.74 90.56 0.88, 0.03 [0.82-0.95] 
Split-Train-Test 84.62 84.62 84.61 0.86, 0.05 [0.76-0.97] 
 
 
 Figure 4: ROC curves of different experiments using Rad, Path, and RadPath features. Left to right are LOO (training), LOO 
(Validation), LOO (Combined), and split-train-test. 
3.3 Survival analysis 
Kaplan–Meier survival curves for both the groups (long- and short-survivors) based on the predictions of 
the proposed model are shown in Fig.5. Both cross-validated model on complete data, and a model 
applied on the validation data after being trained on the training cohort are included. The patients 
predicted to be long- and short-survivors by the model had higher and lower actual survival, respectively. 
The hazard ratio between the predicted long- and short-survivors was 2.867 (95% confidence interval (CI) 
= 1.921-4.278, P < .001), 2.736 (95% CI = 1.831-4.087, P < .001), and 4.33 (95% CI = 2.846-6.587, P < .001) 
for Rad, Path and RadPath datasets, respectively, in the complete cohort. The corresponding hazard in the 
split-train-test setting was 2.665 (95% CI = 1.489-4.771, P < .001), 2.525 (95% CI = 1.403-4.544, P < .001) 
and 5.972 (95% CI = 2.991-11.93, P < .001) for Rad, Path and RadPath datasets, respectively.  
 Figure 5: Kaplan–Meier survival curves. X-axis shows the actual in days and y-axis shows the predictions generated by the 
proposed model. Top-row and bottom row, respectively, show classification results for LOOCV on complete dataset and the split-
train-test experiment. Left to right show Rad, Path, and RadPath features, respectively. 
4. Discussion 
There has been substantial interest in the last decade in ‘radiogenomics’ and ‘pathogenomics’ methods 
where the aim has been to correlate radiological and pathological image features with genomic profiles 
of tumors. Additionally, there is mounting recent interest in developing methods for automatically co-
registering ex-vivo pathology with in-vivo radiographic imaging in order to spatially map disease extent 
from the pathology onto the radiographic imaging16,17.  
Alterations in gene expression implore changes at the vascular and structural level in phenotype of tissue 
that sequentially can be detected on the particular imaging modality under observation. For example, 
morphology of the tumor as seen in tissue slides mimics the aggregate effect of molecular 
alterations/pathways in tumorous cells. Likewise, radiographic imaging sequences highlight structural and 
functional characteristics of the tissue, which reflect biological pathways and cellular morphology 
portraying the tumor cells. Hence, having a panel of computational tools combining histology and 
radiographic sequences is likely to improve our ability to target the right patients with the right 
treatments, and to monitor response over the whole course of the disease. 
In this article, we employed advanced pattern analysis methods in a cohort of glioblastoma patients that 
have undergone in-vivo radiographic and ex-vivo digital pathology imaging. We identified a RadPath based 
imaging signature of the long- and short-survivor glioblastoma patients, and studied biological correlates 
of the topmost distinctive radiographic and pathologic features. Most importantly, the proposed imaging 
signature was derivative of a comprehensive and diverse panel of morphological and physiological 
characteristics of the tumors extracted from radiographic and pathologic images. The individual features 
are not sufficient for identifying long- and short-survivors on a single patient basis; but, suitable 
combination of these features through machine learning accurately identifies long- and short-survivors 
on an individual patient basis, underscoring the value of using a RadPath model that synergistically uses 
all the imaging features extracted from Rad and Path images.   
The proposed method underscores the clinical workflow of radiologists and pathologists by developing 
predictors on radiology and pathology images separately, and by providing integrated diagnosis which 
may lead to interconnected effort between various department for the management of glioblastoma 
patients. In terms of Path images, digitization of tissue slides facilitates the real-time transmission of 
information-rich digital pathology images between different facilities for research, diagnostics, and 
tutoring purposes. This is mainly suitable for acquiring second-opinion on difficult cases and the option to 
provide remote consultation without physically shipping tissue slides across different facilities. The 
digitization of tissue slides may also advance clinical workflow by minimizing the requirement of storing 
glass slides in bio-banks of pathology departments and decreasing the risk of glass tissue slides getting 
damaged. In addition to substantially aiding the radiologists and pathologists in their reporting workflow 
and clinical decision making, the computational tools could facilitate the development of imaging based 
supporting diagnostic assays that could not only allow for improved risk characterization of a disease but 
also enable the integration of diagnostic data coming from different departments for better disease 
management.  
In terms of Rad images, availability of such biomarkers can contribute to non-invasive measurement of 
molecular profile on individual-patient basis. The RadPath approach has the added benefit of both the 
approaches. Contrasting to costly molecular based assays that not only destroy the tissue and assess 
molecular markers from a tiny fraction of the tumor, thereby underestimating tumor heterogeneity, these 
pathology and radiographic imaging (RadPath) based companion diagnostic tools could be made available 
at very reduced price, and could facilitate characterization of the heterogeneity of brain tumors across 
the entire breadth of the tissue specimen or radiographic appearance of the tumor. These tools can help 
in patient stratification into appropriate treatments, and identification of patients with relatively highly 
heterogeneous tumors, who would benefit from more extensive histopathological and molecular analysis 
through multiple samples, as well as by combination treatments. 
Our study is most likely to be immediately translatable to routine clinical settings and to contribute to 
precision medicine owing to the use of standard imaging modalities being routinely acquired in almost all 
the institutions. Moreover, the proposed approach has been evaluated on glioblastoma patients, but is 
generalizable enough to be applicable to other cancer types, especially other brain tumors. Since 
radiographic and pathology imaging both capture spatial heterogeneity of the tumor across the entire 
landscape of the tumor, and are used over time (especially radiographic imaging) to evaluate the 
treatment response in glioblastoma, the proposed RadPath approach for stratification can possibly 
contribute throughout the course of the treatment of the patients. Furthermore, as the field of medicine 
is evolving and the trend towards team-based management of diseases is rapidly increasing, improved 
communication and information exchange between different departments such as radiology and 
pathology is needed more than ever. The proposed RadPath platform provides a mechanism to generate 
coherent, correlated, and integrated diagnostic summaries with nominal additional effort from 
radiologists and pathologists. We believe that a rich set of radiology/pathology features, and the machine 
learning signatures derived from these will enhance our understanding of glioblastoma and can contribute 
to precision diagnostics. 
This work can be extended along various lines: 1) detailed analysis of the discriminative features of both 
the imaging sequences that regression model selects in various cross-validation loops, 2) use of advanced 
deep learning method for jointly using both the imaging sequences, and 3) to perform histology-radiology 
correlation based on the histology-radiology features most discriminative in determining the survival 
outcome. 
 
 
5. Conclusion  
The current standard of diagnosis for brain tumors includes uncoordinated communication/transfer of 
diagnosis reports from radiology and pathology departments to the treating physicians. Any disagreement 
or conflict between these results generally requires added time from the treating physicians to correctly 
diagnose the disease, or given incorrect diagnosis, may unfavorably lead to wrong or sub-optimal 
treatment decisions. To overcome these problems, we proposed and developed a system (pipeline), called 
RadPath, for combining radiology and pathology images for integrated diagnostics. We in fact developed 
a new automated method that synergistically utilizes radiology and pathology imaging sequences, in 
combination and comparison, of glioblastoma patients for assessment of survival outcome of these 
patients. The results of the proposed method on a dataset comprising 107 subjects are quite encouraging 
and prove the effectiveness of the proposed method not only in terms of combined imaging sequences, 
but also on individual imaging sequences as well.  
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